Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18124095 | 1.00 | KDM4E (0.48) | KDM4EMAPTTHRBUSP30TP53 | |
| SCHEMBL16763447 | 0.92 | FPR2 (0.49) | KDM4EMAPTTHRBUSP30MAPK1 | |
| SCHEMBL20986662 | 0.92 | FPR2 (0.49) | KDM4EMAPTTHRBUSP30MAPK1 | |
| SCHEMBL16763448 | 0.92 | FPR2 (0.49) | KDM4EMAPTTHRBUSP30MAPK1 | |
| SCHEMBL2545400 | 0.92 | KDM4E (0.50) | KDM4EMAPTTHRBTP53GPR119 | |
| SCHEMBL29586410 | 0.90 | MAPT (0.46) | KDM4EMAPTTHRBUSP30TP53 | |
| SCHEMBL17582237 | 0.90 | MAPK1 (0.45) | KDM4EMAPTTHRBUSP30TP53 | |
| SCHEMBL16763489 | 0.86 | FPR2 (0.48) | KDM4EMAPTTHRBUSP30HPGD | |
| SCHEMBL16763490 | 0.86 | FPR2 (0.48) | KDM4EMAPTTHRBUSP30HPGD | |
| SCHEMBL17978816 | 0.85 | MAPT (0.42) | KDM4EMAPTTHRBUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707893-A | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-107484415-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-01-29 | — | — | CN | disclosed |
| EP-3255993-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10160751-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. | 2018-12-25 | — | — | US | disclosed |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
| EP-3255993-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9771375-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-26 | — | — | US | disclosed |
| WO-2016127358-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016127358-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-2560962-B1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822447-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| EP-2560962-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | Janssen Pharmaceutica NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133750-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KDM4E 374/4885MAPT 3163/4885THRB 2621/4885 |
| US-10160751-B2 | Inhibitors of the renal outer medullary potassium channel | KCNJ11, KCNJ1, SLC9A1 | KDM4E 2424/4885MAPT 4238/4885THRB 756/4885 |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, SLC9A1 | KDM4E 2424/4885MAPT 4238/4885THRB 756/4885 |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KDM4E 374/4885MAPT 3163/4885THRB 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.